Cognitive Behavioural Therapy for Complicated Grief Reactions in Old Age

August 21, 2025 updated by: University of Aarhus

The Efficacy of Group Versus Individual Cognitive Behavioural Therapy for Complicated Grief Reactions in Old Age: A Randomized Non-inferiority Trial

While most bereaved individuals cope adaptively with the loss of a loved one, a significant minority experiences more severe and complicated grief reactions. Complicated grief reactions is an umbrella term for different types of post-loss complications, including symptoms of Prolonged Grief Disorder (PGD), depression, anxiety, and posttraumatic stress. These post-loss complications may all cause persistent suffering and functional impairment, thus pointing to a need for efficacious treatment.

While Cognitive Behavioural Therapy (CBT) is a relatively well-documented efficacious treatment for symptoms of PGD, depression, anxiety, and posttraumatic stress in the period after a loss, the relative efficacy of a transdiagnostic individually delivered versus group-based CBT for these types of complicated grief reactions (CBTgrief) remain unknown. Furthermore, little evidence exists about the relative cost-effectiveness of individually delivered versus group-based CBTgrief and why and how it works. The theory of CBTgrief proposes that it works by targeting three maintaining mechanisms in PGD: 1) Insufficient integration of the loss, 2) negative loss-related cognitions, and 3) depressive and anxious avoidance. These maintaining mechanisms have also shown to be statistically associated with depression, anxiety, and posttraumatic stress in the period after a loss, suggesting that different types of complicated grief reactions might share some of the same maintaining mechanisms. However, this proposed theory of change has yet to be empirically tested as a whole.

These knowledge gaps are crucial for the understanding of efficacious and cost-effective treatment formats as well as central treatment mechanisms in the psychological treatment of complicated grief reactions. The present study thus aims to examine the relative efficacy of an individually delivered versus group-based CBTgrief by means of a randomized non-inferiority trial. Secondary aims include an investigation of the relative cost-effectiveness of individually delivered versus group-based CBTgrief as well as treatment mediators. Finally, explorative analyses of potential moderators of intervention effects of CBTgrief will be conducted.

Study Overview

Detailed Description

Aims of the study:

  1. Evaluate the relative efficacy of an individually delivered versus group-based CBTgrief.
  2. Evaluate the relative cost-effectiveness of an individually delivered versus group-based CBTgrief.
  3. Examine the theoretically proposed treatment mediators of CBTgrief.
  4. Explore loss-related and sociodemographic characteristics as possible moderators of intervention effects.

Primary hypothesis:

Group-based CBTgrief will show non-inferiority (i.e., equal efficacy) in reducing symptoms of PGD compared to individually delivered CBTgrief at six months follow-up.

Secondary hypotheses:

  1. Group-based CBTgrief will show non-inferiority (i.e., equal efficacy) in reducing symptoms of posttraumatic stress, depression, and anxiety compared to individually delivered CBTgrief at six months follow-up.
  2. Group-based CBTgrief will be more cost-effective than individually delivered CBTgrief.
  3. The observed effect of CBTgrief is mediated by changes in theoretically proposed maintaining mechanisms of complicated grief reactions (i.e. insufficient integration of the loss; negative loss-related cognitions; depressive and anxious avoidance).
  4. Gender, level of education, age, baseline grief symptom level, type of loss, circumstances of the loss, time since loss, and number of additional losses will moderate the observed effects of CBTgrief.
  5. Additional exploratory analyses include an additional matched comparison group, who have not received treatment in order to compare the effect of individual and group-based CBTgrief to a non-treatment group. This group will be extracted from a large-scale survey study: The Aarhus Bereavement Study (NCT03049007). Here, it is hypothesized that CBTgrief will have a statistically significant medium size effect on symptoms of PGD at six months follow-up compared to a matched comparison group, who did not receive treatment.

Design: The present study is conducted as a randomized non-inferiority trial of individually delivered versus group-based CBTgrief using block randomization.

Participants: Participants are recruited from the Danish National Center for Grief (DNCG), which is a Danish national organization that provide specialized psychological therapy to bereaved individuals who have lost a loved one. The therapists at the DNCG will screen and treat bereaved elderly people for complicated grief reactions with CBTgrief at their clinics in Odense and Copenhagen, Denmark. DNCG identifies participants through consultants, local practitioners, self-referral, and the DNCG grief support line.

Assessment points: Participants will be assessed at pre-, mid-, and post-intervention as well as at three and six months follow-up (T1-T5). Additionally, data on healthcare utilization will be retrieved from the Danish national registers concerning use of health care services such as visits to general practitioners, psychologists etc.

Sample size: A group sample size of 2x64 will enable us to detect non-inferiority between individually delivered and group-based CBTgrief with a non-inferiority of -0.5 SD on the primary outcome, i.e. symptoms of PGD, and a statistical power of 0.80. The true difference is assumed to be 0.0 and the one-sided significance level (alpha) of the test is 0.025. Based on an estimated dropout rate of 20% the total number of participants needed to recruit is N=160 participants.

Study Type

Interventional

Enrollment (Actual)

113

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus C, Denmark, 8000
        • Unit for Bereavement Research, Dept. of Psychology, Aarhus University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥ 65 years (older adult).
  2. Lost a loved one (e.g., spouse, partner) ≥ 6 months ago.
  3. Clinically relevant symptoms of one or more types of complicated grief reactions (i.e. symptoms of prolonged grief (PG-13 ≥ 29), depression (CESD-10 ≥ 10), anxiety (GAD-7 ≥ 10), and/or posttraumatic stress (PCL ≥ 31)).

Exclusion Criteria:

  1. No clinically relevant symptoms of one or more types of complicated grief reactions (i.e. symptoms of prolonged grief, depression, anxiety and/or posttraumatic stress).
  2. No informed consent given.
  3. Insufficient Danish proficiency.
  4. Inability to transport oneself to the clinic.
  5. Severe psychopathology (e.g., schizophrenia).
  6. Severe cognitive impairment (e.g., Alzheimer's disease).
  7. Substance abuse.
  8. Acute suicidal ideation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group-based Cognitive Behavioural Therapy
A group delivered treatment format of CBTgrief (12 sessions).

CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.

Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief.

Other Names:
  • Group CBTgrief
Active Comparator: Individually delivered Cognitive Behavioural Therapy
An individual delivered treatment format of CBTgrief (12 sessions).

CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.

Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief.

Other Names:
  • Individual CBTgrief

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptoms of prolonged grief disorder
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session) and to six months follow-up (T5).
Changes in symptoms of prolonged grief disorder will be measured with Prolonged Grief Disorder-13 (PG-13; Prigerson et al., 2009). Higher total scores indicate higher symptom level (minimum value: 11; maximum value: 57).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session) and to six months follow-up (T5).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depressive symptoms
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in depressive symptoms will be measured with Center for Epidemiologic Studies Short Depression Scale (CESD-10; Andresen, Malmgren, Carter, & Patrick, 1994). Higher total scores indicate higher symptom level (minimum value: 0; maximum value: 30).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Anxiety symptoms
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in anxiety symptoms will be measured with Generalized Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006). Higher total scores indicate higher symptom level (minimum value: 0; maximum value: 21).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Posttraumatic stress symptoms
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in posttraumatic stress symptoms will be measured with Posttraumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) (PCL; Ashbaugh, Houle-Johnson, Herbert, El-Hage, & Brunet, 2016; Weathers et al., 2013). Higher total scores indicate higher symptom level (minimum value: 0; maximum value: 80).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Quality adjusted life years
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in quality adjusted life years will be assessed with 5Q-5D-5L (EuroQol Research Foundation, 2019) and used in order to evaluate cost-effectiveness.
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Functional impairment
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in functional impairment will be measured with Sheehan Disability Scale (SDS; Leon, Olfson, Portera, Farber, & Sheehan, 1997). Higher total scores indicate greater functional impairment (minimum value: 0; maximum value: 30).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Loneliness
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in loneliness will be measured with Three-Item Loneliness Scale (TILS; Hughes, Waite, Hawkley, & Cacioppo, 2004). Higher total scores indicate greater loneliness (minimum value: 3; maximum value: 9).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Mental and physical function
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in mental and physical function will be measured with 12-Item Short Form Health Survey (SF-12; Ware, Kosinski, & Keller, 1996).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Social support
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in social support will be measured with Crisis Social Support scale (CSS; Joseph, Andrews, Williams, & Yule, 1992). Higher total scores indicate higher level of support (minimum value: 7; maximum value: 49).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Well-being
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in well-being will be measured with the five-item WHO Well-Being Index (WHO-5; Heun, Bonsignore, Barkow, & Jessen, 2001). Higher total scores indicate higher well-being (minimum value: 0; maximum value: 100).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Symptoms of prolonged grief disorder (at three months follow-up)
Time Frame: From baseline (T1) to three months follow-up (T3).
Changes in symptoms of prolonged grief disorder will be measured with Prolonged Grief Disorder-13 (PG-13; Prigerson et al., 2009). Higher total scores indicate higher symptom level (minimum value: 11; maximum value: 57).
From baseline (T1) to three months follow-up (T3).
Symptoms of ICD-11 prolonged grief disorder
Time Frame: From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).
Changes in symptoms of ICD-11 prolonged grief disorder (i.e. the 11th revision of the International Classification of Diseases definition) will be measured by mapping questionnaire items from Prolonged Grief Disorder-13 (PG-13; Prigerson et al., 2009); Inventory of Complicated Grief Revised (ICG-r; Prigerson & Jacobs, 2001); Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5; Ashbaugh et al., 2016; Weathers et al., 2013).
From baseline (T1) to post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), and six months follow-up (T5).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mediator: Insufficient integration of the loss
Time Frame: Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Changes in the integration of the loss will be measured with Experienced Unrealness Scale (EUS; Boelen, 2010). Higher total scores indicate greater sense of unrealness (minimum value: 5; maximum value: 40).
Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Mediator: Negative loss-related cognitions
Time Frame: Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Changes in grief-related cognitions will be measured with Grief Cognitions Questionnaire (GCQ; Boelen & Lensvelt-Mulders, 2005). Higher total scores indicate higher levels of negative loss-related cognitions (minimum value: 0; maximum value: 90).
Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Mediator: Avoidance behaviors
Time Frame: Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Changes in avoidance behaviors will be measured with Depressive and Anxious Avoidance in Prolonged Grief Questionnaire (DAAPGQ; Boelen & van den Bout, 2010). Higher total scores indicate higher levels of avoidance behaviors (minimum value: 9; maximum value: 63).
Baseline (T1), mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session), three months follow-up (T4), six months follow-up (T5).
Mediator: Therapeutic alliance
Time Frame: Mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session).
Changes in the therapeutic alliance will be measured with Working Alliance Inventory - Short Form (WAI-SF; Horvath & Greenberg, 1989; Tracey & Kokotovic, 1989).
Mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session).
Mediator: Therapeutic group processes
Time Frame: Mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session).
Changes in therapeutic group processes will be measured with Therapeutic Factors Inventory - Short Form (TFI-SF; Joyce, MacNair-Semands, Tasca, & Ogrodniczuk, 2011).
Mid-intervention (T2; immediately after the 6th session), post-intervention (T3; up to one week after the 12th session).
Healthcare utilization costs
Time Frame: Baseline (T1) to six months follow-up (T5).
Data about visits to general practitioners, psychologists etc. delivered by the Danish Health Data Authority.
Baseline (T1) to six months follow-up (T5).
Moderator: Circumstances of the loss
Time Frame: Measured at baseline (T1).
Data about circumstances of the loss (e.g., traumatic, non-traumatic) will be explored as a possible moderator.
Measured at baseline (T1).
Moderator: Type of loss
Time Frame: Measured at baseline (T1).
Data about type of loss (e.g., spouse, child) will be explored as a possible moderator.
Measured at baseline (T1).
Moderator: Time since loss
Time Frame: Measured at baseline (T1).
Data about time since loss will be explored as a possible moderator.
Measured at baseline (T1).
Moderator: Baseline grief symptom level
Time Frame: Measured at baseline (T1).
Grief symptom level prior to intervention will be measured with Prolonged Grief Disorder-13 (PG-13; Prigerson et al., 2009) and explored as possible moderator.
Measured at baseline (T1).
Moderator: Number of additional losses
Time Frame: Measured at baseline (T1).
Data about number of additional losses will be explored as a possible moderator.
Measured at baseline (T1).
Moderator: Sociodemographic characteristics (e.g., gender, age, level of education)
Time Frame: Measured at baseline (T1).
Data about gender, age, level of education will be explored as possible moderators.
Measured at baseline (T1).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Maja O'Connor, PhD, University of Aarhus

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2021

Primary Completion (Actual)

May 31, 2025

Study Completion (Actual)

May 31, 2025

Study Registration Dates

First Submitted

December 16, 2020

First Submitted That Met QC Criteria

January 4, 2021

First Posted (Actual)

January 5, 2021

Study Record Updates

Last Update Posted (Actual)

August 22, 2025

Last Update Submitted That Met QC Criteria

August 21, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions

Subscribe